Cancer Prevention Pharmaceuticals is developing therapeutics to reduce the risk and reocurrence of cancer and other diseases.
In partnership with Mallinckrodt Plc, CPP is sponsoring the FAP-310 Pivotal Phase 3 Trial of our lead product, CPP-1X/sul, for Familial Adenomatous Polyposis (FAP). CPP-1X/sul has been granted “Fast Track” and “Orphan Drug” designation from FDA. All patients have completed treatment and trial results are expected in the first quarter of 2019.
CPP is also working collaboratively with research institutions and nonprofit groups in support of their clinical trials in neuroblastoma, gastric cancer and early-onset type 1 diabetes.
We were founded by highly respected leaders in preclinical and clinical cancer prevention research. The CPP team has significant experience in drug development, research, and commercialization.